Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Contact
  • Restricted
Select Page
Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV

Data from ODYSSEY are used by ViiV Healthcare to file FDA and EMA submissions for the first-ever dispersible formulation of dolutegravir for children living with HIV

by Andrea Canton | Dec 20, 2019 | Odyssey

Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...

Recent Posts

  • What does COVID-19 mean for those living in HIV communities?
  • ODYSSEY trial: COVID-19 response and CROI update
  • Adeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years
  • Adeqaute dolutegravir exposure dosed BID with rifampicin in children 6 to < 18 years
  • ODYSSEY to be presented at CROI 2020

Recent Comments

    Archives

    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • Odyssey
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is PENTA Foundation